Cargando…

The value of serum type II collagen epitope measurement in assessing early clinical response to treatment with anti-tumour necrosis factor alpha therapy in rheumatoid arthritis

Detalles Bibliográficos
Autores principales:	Mullan, RH, Lobanok, T, Walsh, C, King, L, FitzGerald, O, Bresnihan, B, Fearon, U, Poole, R, Veale, DJ
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834059/ http://dx.doi.org/10.1186/ar1581

Ejemplares similares

Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
por: Fearon, U, et al.
Publicado: (2005)

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies
por: Moran, Ellen M, et al.
Publicado: (2009)

Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease
por: Walsh, Ceara E., et al.
Publicado: (2011)

Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis
por: Minnock, Patricia, et al.
Publicado: (2015)

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder
por: Balogh, Emese, et al.
Publicado: (2013)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)

Peripheral corticotropin releasing hormone signaling is mediated by Type 1alpha receptors in early human inflammatory arthritis
por: McEvoy, A, et al.
Publicado: (2001)

Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue
por: O'Hara, Rosemary, et al.
Publicado: (2000)

Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?
por: Bresnihan, Barry, et al.
Publicado: (2004)

Remission in psoriatic arthritis: is it possible and how can it be predicted?
por: Saber, Tajvur P, et al.
Publicado: (2010)

Synovial tissue hypoxia and inflammation in vivo
por: Ng, C T, et al.
Publicado: (2010)

Inmunohistologic analysis of synovial tissue from early and late osteoarthritic patients. A potential role for COX-2 and NF-κB1 (p50) regulation in early disease
por: Benito, MJ, et al.
Publicado: (2002)

Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study
por: Pontifex, Eliza K, et al.
Publicado: (2011)

What makes psoriatic and rheumatoid arthritis so different?
por: Veale, Douglas James, et al.
Publicado: (2015)

ACPA Status Correlates with Differential Immune Profile in Patients with Rheumatoid Arthritis
por: Floudas, Achilleas, et al.
Publicado: (2021)

CD209/CD14(+) Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration, and Therapeutic Targeting
por: Marzaioli, Viviana, et al.
Publicado: (2022)

Randomised controlled trial examining the effect of exercise in people with rheumatoid arthritis taking anti-TNFα therapy medication
por: Reid, Angela, et al.
Publicado: (2011)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
por: Biniecka, Monika, et al.
Publicado: (2011)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Therapeutic inhibition of tumour necrosis factor alpha reduces oligoclonality in the selected T-cell receptor BV families in rheumatoid arthritis
por: Pierer, M, et al.
Publicado: (2003)

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
por: Stavropoulos-Kalinoglou, Antonios, et al.
Publicado: (2012)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Tumour necrosis factor in man: clinical and biological observations.
por: Selby, P., et al.
Publicado: (1987)

Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.
por: Pusztai, L., et al.
Publicado: (1994)

Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology
por: Tse, Brian W. C., et al.
Publicado: (2012)

Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha
por: Stanilov, Noyko, et al.
Publicado: (2014)

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
por: Ruder, Barbara, et al.
Publicado: (2019)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Acute Serum Amyloid A induces cell migration cytoskeletal rearrangement and Notch signalling in rheumatoid arthritis
por: Connolly, Mary, et al.
Publicado: (2012)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Autocrine self-elimination of cultured ovarian cancer cells by tumour necrosis factor alpha (TNF-alpha).
por: Simonitsch, I., et al.
Publicado: (1998)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Early biomarkers of joint damage in rheumatoid and psoriatic arthritis
por: Mc Ardle, Angela, et al.
Publicado: (2015)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.
por: van der Zee, J., et al.
Publicado: (1995)

The neutrophil migration induced by tumour necrosis factor alpha in mice is unaffected by glucocorticoids
por: Cecilio, C. A., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_cnq79vndt5mvqb849t3po5m2gi